Filtered By:
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 2124 results found since Jan 2013.
Reimbursement for HPV Vaccine Cost in the Private Sector: A Comparison Across Specialties
This study found that net returns from HPV vaccine cost reimbursements are lowest for family physicians ($0.34/dose) and highest for pediatricians ($5.08/dose). Furthermore, a $1 increment in return was associated with an increase in HPV vaccine doses administered (highest for family physicians; 0.08% per dollar). Reimbursement for HPV vaccine costs by private payers is adequate; however, return margins are small for non-pediatric specialties.PMID:37487718 | PMC:PMC10365861 | DOI:10.1370/afm.2990
Source: Annals of Family Medicine - July 24, 2023 Category: Primary Care Authors: Yenan Zhu Yueh-Yun Lin Ruosha Li Cara He David R Lairson Ashish A Deshmukh Kalyani Sonawane Source Type: research
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial
This study aimed to compare the immunogenicity of the E coli-produced HPV 9-valent vaccine Cecolin 9 (against HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) with Gardasil 9.METHODS: This was a randomised, single-blind trial conducted in China. Healthy non-pregnant women aged 18-26 years, who were not breastfeeding and with no HPV vaccination history, were enrolled in the Ganyu Centre for Disease Control and Prevention (Lianyungang City, Jiangsu Province, China). Women were stratified by age (18-22 years and 23-26 years) and randomly assigned (1:1) using a permutated block size of eight to receive three doses of Cecolin 9 or Ga...
Source: Cancer Control - July 20, 2023 Category: Cancer & Oncology Authors: Feng-Cai Zhu Guo-Hua Zhong Wei-Jin Huang Kai Chu Li Zhang Zhao-Feng Bi Kong-Xin Zhu Qi Chen Ting-Quan Zheng Ming-Lei Zhang Sheng Liu Jin-Bo Xu Hong-Xing Pan Guang Sun Feng-Zhu Zheng Qiu-Fen Zhang Xiu-Mei Yi Si-Jie Zhuang Shou-Jie Huang Hui-Rong Pan Ying-Y Source Type: research
Advances in HPV-associated tumor management: Therapeutic strategies and emerging insights
J Med Virol. 2023 Jul;95(7):e28950. doi: 10.1002/jmv.28950.ABSTRACTWith the rapid increase in the incidence of cervical cancer, anal cancer and other cancers, human papillomavirus (HPV) infection has become a growing concern. Persistent infection with high-risk HPV is a major cause of malignant tumors. In addition, microbiota and viruses such as human immunodeficiency virus, herpes simplex virus, and Epstein-Barr virus are closely associated with HPV infection. The limited effectiveness of existing treatments for HPV-associated tumors and the high rates of recurrence and metastasis in patients create an urgent need for nov...
Source: Herpes - July 19, 2023 Category: Infectious Diseases Authors: Xiangjin Gong Hao Chi Zhijia Xia Guanhu Yang Gang Tian Source Type: research
Human papillomavirus vaccine acceptance among adolescent girls in Ethiopia: a systematic review and meta-analysis
CONCLUSION: Human papillomavirus vaccine acceptance of adolescent girls in Ethiopia was low. Knowledge about the vaccine and attitude to vaccination were positively associated with their vaccine acceptance. Therefore, policymakers and program planners should target school-aged adolescents in increasing their awareness and changing their attitudes to enhance their vaccine acceptance in order to prevent and control cervical cancer.PMID:37461006 | DOI:10.1186/s12889-023-16305-3
Source: Cancer Control - July 17, 2023 Category: Cancer & Oncology Authors: Amare Zewdie Abebaw Wasie Kasahun Adane Habtie Anteneh Gashaw Mulat Ayele Source Type: research
Dual anti-PD-(L)1/TGF- β inhibitors in cancer immunotherapy - Updated
Int Immunopharmacol. 2023 Jul 15;122:110648. doi: 10.1016/j.intimp.2023.110648. Online ahead of print.ABSTRACTImmune checkpoint inhibitor (ICI) therapy suffers from tumor resistance and relapse in majority of patients due to the suppressive tumor immune microenvironment (TIME). Advances in the field have brought about development of fusion proteins able to target two signaling simultaneously and to exert maximal anti-cancer immunity. Bispecific inhibitors of transforming growth factor (TGF)-β signaling and programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) are developed to reduce the rate of relapse and to ach...
Source: International Immunopharmacology - July 17, 2023 Category: Allergy & Immunology Authors: Zana Karami Keywan Mortezaee Jamal Majidpoor Source Type: research
